# AeroRx Therapeutics Inc.: Phase 1 study completed, 24 enrolled (COPD (Chronic Obstructive Pulmonary Disease))

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | AeroRx Therapeutics Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients |
| NCT ID | NCT07802730 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | COPD (Chronic Obstructive Pulmonary Disease) |
| Intervention types | drug |
| Target enrollment | 24 |
| Site countries | United Kingdom |
| Posted | 2026-09-03 |
| Planned start | 2026-09-21 |
| Event | Completed |
| Event date | 2026-10-09 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07802730). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.